- Home
- About
- PsychU For You
- Topics
- Mental Health Disorders
- Agitation
- Bipolar Disorder
- Depression
- Pseudobulbar Affect (PBA)
- PTSD/Trauma
- Schizophrenia
- Substance Use Disorders
- Topics of Interest
- Care Coordination
- Digital Health
- Diversity, Equity, & Inclusion
- Health Care Policy, Quality & Payer Administration
- Long-Term Care
- Stigma
- Suicide Awareness
- Wellness
- Events
- Content
- Supporting Organizations
Virtual Event – Trace Amine-Associated Receptor 1 (TAAR1): A Potential New Target For The Treatment Of Schizophrenia

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Virtual Event – Trace Amine-Associated Receptor 1 (TAAR1): A Potential New Target For The Treatment Of Schizophrenia
This is a Virtual Live Event for PsychU Members in Alaska, Oregon, and Washington.
Trace amines and trace amine-associated receptors (TAAR) are found throughout the brain and peripheral tissues and have modulating effects on neurotransmitters including dopamine, glutamate, and serotonin. The speakers will discuss what are some of the potential effects of TAAR1 on neurotransmitter signaling related to schizophrenia and some of the preclinical data, as well as share the potential role of TAAR1 beyond schizophrenia.
Objectives:
- Summarize the Unmet Needs of Schizophrenia as it Relates to Neural Circuitry
- Introduction to Trace Amines (TA) and Trace Amine-Associated Receptors (TAARs) and Their Potential Relationship to Schizophrenia
- Discuss Potential Modulating Effects of TAAR1 on Neurotransmitter Signaling Associated with Schizophrenia Pathophysiology

Chet Robachinski, MD
Psychiatric Director, Bailey-Boushay House, Seattle, WA; Founding Partner, Associates in Behavioral Health

Simon Kim, PharmD
Medical Science Liaison
Speaker Chet Robachinski, MD is a paid consultant for Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
Speaker Simon Kim, PharmD is an employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)